Development of p300-targeting degraders with enhanced selectivity and onset of degradation
Open Access
- 3 March 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (5) , 2049-2060
Abstract
P300 and CBP are paralogous epigenetic regulators and promising therapeutic targets for which TPD offers the potential to achieve paralog-selective degradation.Keywords
Funding Information
- Children's Cancer Research Fund
- Paula and Rodger Riney Foundation
- Congressionally Directed Medical Research Programs (HT9425-23-1-0456)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR055685)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR081228)
This publication has 34 references indexed in Scilit:
- Targeting p300 Addiction inCBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation ofMYCExpressionCancer Discovery, 2016
- Protein Lysine Acetylation by p300/CBPChemical Reviews, 2015
- Super-Enhancers in the Control of Cell Identity and DiseaseCell, 2013
- Differences in Specificity and Selectivity Between CBP and p300 Acetylation of Histone H3 and H3/H4Biochemistry, 2013
- Genome-wide assessment of differential roles for p300 and CBP in transcription regulationNucleic Acids Research, 2010
- The structural basis of protein acetylation by the p300/CBP transcriptional coactivatorNature, 2008
- Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewalProceedings of the National Academy of Sciences, 2002
- The Sizes of Peptides Generated from Protein by Mammalian 26 and 20 S ProteasomesJournal of Biological Chemistry, 1999
- The CBP co-activator is a histone acetyltransferaseNature, 1996
- The Transcriptional Coactivators p300 and CBP Are Histone AcetyltransferasesCell, 1996